Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild to Moderate Atopic Dermatitis Clear all
Completed Phase 2 Interventional

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

NCT00076375
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Nanocrystalline silver cream (NPI)
Drug
Lead sponsor
Nucryst Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT01826461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PDI-192, Vehicle
Drug
Lead sponsor
PreCision Dermatology, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
San Diego, California • Chicago, Illinois • Normal, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

NCT00120523
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Topical corticosteroids
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
3 Months to 12 Months
Enrollment
2,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

NCT04504279
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB-401, Placebo
Biological
Lead sponsor
Forte Biosciences, Inc.
Industry
Eligibility
2 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Fremont, California • Lake City, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

NCT01232985
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
RD047-26
Device
Lead sponsor
Oculus Innovative Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2012 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema

NCT05918237
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Arctiva
Other
Lead sponsor
ClinOhio Research Services, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

NCT05571943
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

NCT03107611
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Placebo Cream
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
8 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 4 Interventional Results available

Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis

NCT01093469
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Atopiclair Nonsteroidal Cream, Aquaphor Healing Ointment, EpiCeram
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

NCT00697710
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
50 mg S-777469, 200 mg S-777469, 800 mg S-777469, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 5, 2026, 1:30 AM EDT
Recruiting No phase listed Observational

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

NCT06259669
View directory record Official record
Conditions
Pregnancy Related, Atopic Dermatitis
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
958 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin

NCT02120833
View directory record Official record
Conditions
Eczema
Interventions
EpiCeram® Skin Barrier Emulsion, Colloidal Oatmeal Cream
Device · Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Months to 35 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

NCT03356977
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment 2%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 23 Months
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Hot Springs, Arkansas • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 5, 2026, 1:30 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

NCT03351777
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PR022
Drug
Lead sponsor
Realm Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

NCT00121316
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

NCT00125333
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
NF-kappaB Decoy
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Miami, Florida • Fridley, Minnesota • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

NCT04040192
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

NCT04313400
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2
Drug
Lead sponsor
Amytrx Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Cerritos, California • Encino, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 5, 2026, 1:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
Drug
Lead sponsor
Clinical Research Center of the Carolinas
Other
Eligibility
2 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

NCT06024499
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Interventions
HY209GEL Active, Placebo
Drug · Other
Lead sponsor
Shaperon
Industry
Eligibility
18 Years to 100 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Encino, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Not listed Phase 4 Interventional

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

NCT04214197
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Top Oint
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 5, 2026, 1:30 AM EDT